Ciphero | $2,500,000 | (Dec 23, 2025)
beycome | $2,500,000 | (Dec 23, 2025)
Givefront | $2,000,000 | (Dec 23, 2025)
Certified by Founder
Lodge
Illimis Therapeutics
start up
Korea, Republic Of
- Seoul
- 15/07/2025
- Series B
- $42,000,000
Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimer’s. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from existing antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells.
- Industry Biotechnology Research
- Website www.illimistx.com
- LinkedIn https://www.linkedin.com/company/illimis-therapeutics/
StretchSense | $2,300,000 | (Dec 23, 2025)
ZeroPhase | $6,800,000 | (Dec 23, 2025)
Peripheral Labs | $3,600,000 | (Dec 23, 2025)
Ethereal Exploration Guild | $21,000,000 | (Dec 23, 2025)
LatentForce | $1,700,000 | (Dec 23, 2025)
arcads AI | $16,000,000 | (Dec 19, 2025)
Amphix Bio | $12,500,000 | (Dec 19, 2025)
Edison Scientific | $70,000,000 | (Dec 19, 2025)
Thread | $18,000,000 | (Dec 19, 2025)